Valuation: Colinz Laboratories Limited

Market Cap 112M 1.17M 1.02M 955K 868K 1.63M 1.66M 11.18M 4.37M 56.23M 4.41M 4.31M 187M P/E 2024
19.5x
P/E 2025 36.8x
Enterprise Value 63.01M 660K 571K 537K 488K 916K 933K 6.28M 2.46M 31.6M 2.48M 2.43M 105M EV / Sales 2024
0.43x
EV / Sales 2025 2.04x
Free-Float
31.44%
Yield 2024 *
-
Yield 2025 -
07-30 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-17 Annjana Dugar, Likhitta Dugar and Antariksh Dugar executed of Share Purchase Agreement to acquire an additional 34.56% stake in Colinz Laboratories Limited from Vijaya Mani for INR 43.5 million, CI
06-17 Annjana Dugar, Likhitta Dugar and Antariksh Dugar proposed to acquire an additional 26% stake in Colinz Laboratories Limited for INR 35.4 million. CI
05-25 Padam Dugar, Annjana Dugar, Likhitta Dugar and Antariksh Dugar acquired 15.01% stake in Colinz Laboratories Limited. CI
04-29 Colinz Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
01-24 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
01-16 Hilsun Foods And Drugs Private Limited signed a letter of intent to acquire Factory Building, Factory Machinery, & Factory Land of Colinz Laboratories Limited for INR 40 million. CI
11-27 Colinz Laboratories Limited Appoints Falguni Kumawat as Company Secretary and Compliance Officer, with Effect from 1 December, 2025 CI
11-08 Colinz Laboratories Limited Announces of Demise Dr. Mani L.S., Founder Director, Company Secretary and Compliance Officer on 7 November 2025 CI
11-03 Colinz Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
31/07/25 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
21/05/25 Colinz Laboratories Limited Appoints Swapnil Jayesh Madiyar as Additional Director, Effective from May 16, 2025 CI
16/05/25 Colinz Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
1 day-4.06%
1 week-2.54%
Current month-2.60%
1 month+10.96%
3 months+67.83%
6 months+58.85%
Current year+48.93%
1 week 76.15
Extreme 76.15
84.5
1 month 70.49
Extreme 70.49
85.99
Current year 39.31
Extreme 39.31
87.91
1 year 36.11
Extreme 36.11
87.91
3 years 35.2
Extreme 35.2
88.7
5 years 15.55
Extreme 15.55
88.7
10 years 4.8
Extreme 4.8
88.7
Manager TitleAgeSince
Chief Executive Officer 74 -
Director of Finance/CFO - 19/05/2019
Compliance Officer - 30/11/2025
Director TitleAgeSince
Director/Board Member 74 25/11/1990
Director/Board Member 33 07/08/2024
Director/Board Member 76 07/08/2024
Change 5-day change 1-year change 3-year change Capi.($)
-4.06%-2.54%+80.87%+112.99% 2.2M
-0.10%-1.08%+17.70%+70.44% 48.57B
-3.26%-1.15%+50.36%+115.32% 40.99B
-0.60%-1.83%-7.11%+15.98% 12.35B
-2.75%+2.45%+14.83%+74.39% 12.2B
-0.19%-0.19%+29.10%+135.91% 9.08B
+1.56%+7.62%+23.93%+39.78% 7.41B
+0.52%+3.93%+39.82%-13.06% 7.13B
-0.07%+2.13%+14.25%+189.31% 6.86B
-2.51%+3.10%-27.59%+27.09% 5.92B
Average -1.15%+1.51%+23.61%+76.82% 15.05B
Weighted average by Cap. -1.20%+1.03%+24.43%+80.72%

Financials

2024 2025
Net sales 70.3M 737K 637K 599K 544K 1.02M 1.04M 7.01M 2.74M 35.26M 2.77M 2.71M 117M 65.28M 684K 591K 556K 506K 949K 966K 6.51M 2.55M 32.74M 2.57M 2.51M 109M
Net income 4.87M 51.01K 44.09K 41.47K 37.69K 70.78K 72.04K 485K 190K 2.44M 192K 187K 8.13M 4.97M 52.05K 44.98K 42.32K 38.46K 72.22K 73.5K 495K 194K 2.49M 195K 191K 8.29M
Net Debt -64.3M -674K -582K -548K -498K -935K -952K -6.41M -2.51M -32.25M -2.53M -2.48M -107M -49.09M -515K -445K -418K -380K -714K -727K -4.9M -1.92M -24.63M -1.93M -1.89M -82M
Logo Colinz Laboratories Limited
Colinz Laboratories Ltd. is an India-based company that is engaged in the manufacturing and marketing of pharmaceutical formulations, particularly in the gynecological sector. It is engaged in the manufacturing and marketing various allopathic, ayurvedic, and nutraceuticals pharmaceutical formulations in the dosage forms of tablets, capsules, liquid orals and ointments, among others. The company has specialized products for Gynecology, cardiology, gastroenterology, and others. Its oncology products include imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, and doxorubicin. Its Ayurvedic products include anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, and memory boosters. Its nutraceuticals products include spirulina tabs/caps, spirulina with vitamins & minerals, omega 3 fatty acid caps in softgel, codliver oil with vitamin caps in soft gel, collagen, and glucosamine & chondroitin tabs.
Employees
65
Date Price Change Volume
14/08/26 ₹79.87 -4.06% 309
13/08/26 ₹83.25 +2.15% 2,500
12/08/26 ₹81.50 +2.28% 15,244
11/08/26 ₹79.68 +0.01% 246
10/08/26 ₹79.67 -4.47% 756
  1. Stock Market
  2. Stocks
  3. COLINZ6 Stock